October Research Reports on Drugs and Biotechnology Published by MarketPublishers.com

LONDON--(BUSINESS WIRE)-- Market Publishers Ltd informs that new in-demand market reports on Drugs & Biotechnology are available in its catalogue.

Renal Cell Carcimona Cancer Drug Futures. The report provides estimated forecast of the number of renal cell carcinoma (RCC) patients and the total RCC sales (up to almost US$6.5 billion) for branded products by 2015. The report says that these figures are expected to grow and analyzes factors (the number of treatment options, improvements in drug efficacy, the use of drug therapy earlier in the course of the disease, etc.) that could influence it … http://marketpublishers.com/r/R3AC1F884B0EN.html

Breast Сancer Drug Futures. The report provides an overview of existing treatments resulting in a longer duration of therapy, decreasing mortality levels and novel treatments with targeted monoclonal antibodies and small-molecule inhibitors that are predicted to be used in combination with chemotherapy and hormonal therapy. The analysis of a five-year survival rates shows an increase from under 70% 50 years ago to around 90% now … http://marketpublishers.com/r/BA82292AE57EN.html

Lung Cancer Drug Futures. Insisting on the fact that the lung cancer market is set for radical change the report analyzes the market situation in terms of current first-line therapies (anti-angiogenic VEGF inhibitor Avastin (bevacizumab) and small-molecule tyrosine kinase inhibitor Tarceva (erlotinib)), generic competition in the short term, better-tolerated biologics which are forecast to increase from 30% to 60% by 2014 … http://marketpublishers.com/r/L1A038CE0E4EN.html

Prostate Cancer Drug Future. With the imminent arrival of new targeted therapies the prostate cancer (PC) market is said to be on the verge of considerable change, the report provides statistics over the last 25 years and estimates the market value at US$5.2 billion in 2008. It says that the market dynamics will change considerably over the next six years and provides grounds to supplement it … http://marketpublishers.com/r/P3DCC66A6CFEN.html

Colorectal Сancer Drug Future. The report delves into the stages of the disease evolvement, figures out trends in the disease treatment, provides statistics of the CRC drug market (US, EU and Japan) development, the overview of major branded therapies and predicts the future use of a therapy type and for a 77% of the CRC market to use targeted therapies … http://marketpublishers.com/r/CB79BD7FA04EN.html

New reports on Drugs & Biotechnology can be found at http://marketpublishers.com/catalog/drugs_biotechnology.html



CONTACT:

TD The Market Publishers, Ltd.
Mrs. Alla Martin
Tel: +44 208 123 2220
Fax: +44 207 900 3970
[email protected]
www.marketpublishers.com

KEYWORDS:   United Kingdom  Europe

INDUSTRY KEYWORDS:   Health  Biotechnology  Medical Devices  Oncology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

In an era of limited access to key decision makers, how are you mobilizing your field force to communicate the value of your brands and real-world evidence?

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.

Biosims to Roche's Big 3 cancer drugs will chisel out a $10 billion sales gap by 2023, but newer meds could chip in $16.3 billion, the drugmaker says.